No definition available.

Name:	ird_CollaborationAndLicenseAgreementAbstract
Namespace Prefix:	ird_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, after allowance for credit loss, of right to consideration upon the completion of services to customer when right is conditioned on something other than passage of time, classified as current.

+ References

No definition available.

+ Details

Name:	ird_ContractAssetCurrent
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

This line item represents amounts invoiced that were previously reflected in the Contract Asset account.

+ References

No definition available.

+ Details

Name:	ird_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of milestone payment received upon achieving performance obligation.

+ References

No definition available.

+ Details

Name:	ird_FirstMilestonePaymentToBeReceived
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone payments receivable upon the achievement of development, regulatory and commercial goals.

+ References

No definition available.

+ Details

Name:	ird_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum percentage of tiered royalties receivable based on the aggregate annual net sales of all Nyxol Products in the United States.

+ References

No definition available.

+ Details

Name:	ird_MaximumPercentageOfTieredRoyaltiesReceivable
Namespace Prefix:	ird_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of milestone payment to be recognized as revenue.

+ References

No definition available.

+ Details

Name:	ird_MilestonePaymentIncludedInRevenueFromContractWithCustomerToBeRecognized
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of milestone payment met by the entity which required FDA's approval.

+ References

No definition available.

+ Details

Name:	ird_MilestonePaymentRequiredUnderFDASApproval
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Non-cancellation period of constrained, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	ird_NonCancellationPeriodOfConstrained
Namespace Prefix:	ird_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of non-refundable cash payments received during the period under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ird_NonRefundableCashPaymentReceived
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The number of performance obligations in accordance with the provisions under ASC 606, the Company identified.

+ References

No definition available.

+ Details

Name:	ird_NumberOfPerformanceObligations
Namespace Prefix:	ird_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of cash outflows for royalty payments related to the sale of a product.

+ References

No definition available.

+ Details

Name:	ird_RoyaltyPayments
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- References

No definition available.

+ Details

Name:	us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=ird_ViatrisLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=ird_LicenseTransferFeeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_HealthCareOrganizationRevenueSourcesAxis=ird_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreements, Viatris License Agreement (Details) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 25, 2023 USD ($)	Nov. 30, 2022 USD ($)	Sep. 30, 2024 USD ($) Performanceobligation	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Performanceobligation	Sep. 30, 2023 USD ($)	Nov. 06, 2022 USD ($)
Collaboration and License Agreement [Abstract]
Revenue recognized			$ 3,867	$ 11,935	$ 6,690	$ 17,358
Reconciliation of Closing Balance of Contract Asset [Abstract]
Revenue recognized			$ 3,867	11,935	$ 6,690	17,358
Viatris License Agreement [Member]
Collaboration and License Agreement [Abstract]
Non-refundable cash payment received		$ 35,000
Maximum amount of payments receivable for development, regulatory and commercial milestones							$ 130,000
Milestone payments to be received							$ 10,000
Maximum percentage of tiered royalties receivable			20.00%		20.00%
Number of distinct performance obligations \| Performanceobligation			2		2
Non-cancellation period of constrained					120 days
Royalty payments			$ 14		$ 36
Milestone payment included in revenue recognition	$ 10,000
Revenue recognized			3,900	11,900	6,690	17,358
Reconciliation of Closing Balance of Contract Asset [Abstract]
Beginning Balance					1,407	3,552
Revenue recognized			3,900	11,900	6,690	17,358
Ending Balance			$ 1,468	1,211	1,468	1,211
Viatris License Agreement [Member] \| License Transfer Fee [Member]
Reconciliation of Closing Balance of Contract Asset [Abstract]
Reclassification to accounts receivable related to costs billed under the Viatris License Agreement					(6,629)	(19,699)
Viatris License Agreement [Member] \| Sales Milestones [Member]
Collaboration and License Agreement [Abstract]
Milestone payment requirements attributed to the FDA's approval				10,000		10,000
Revenue recognized				10,000	0	10,000
Reconciliation of Closing Balance of Contract Asset [Abstract]
Revenue recognized				$ 10,000	$ 0	$ 10,000